Abstract
[3H]MPP+ (1-[methyl-3H]4-phenylpyridinium) is taken up into rat striatal slices in a temperature-, time- and Na+-dependent process blocked by dopamine (DA) uptake inhibitors. Once taken up, authentic [3H]MPP+ is released at 37 degrees C by 15 mM KCl. This release is inhibited by (-)N-propyl-norapomorphine and enhanced by (-)sulpiride, as observed under the same conditions for [3H]DA release. Thus, rat striatal DA-ergic nerve endings do not discriminate between DA and MPP+ for their active transport and DA autoreceptor-regulated release.
MeSH terms
-
1-Methyl-4-phenylpyridinium
-
Animals
-
Apomorphine / analogs & derivatives
-
Apomorphine / pharmacology
-
Corpus Striatum / metabolism*
-
Dopamine / analysis
-
Dopamine / metabolism*
-
Dopamine Antagonists
-
In Vitro Techniques
-
Isoquinolines / pharmacology
-
Male
-
Neurons / metabolism
-
Piperazines / pharmacology
-
Potassium Chloride / pharmacology
-
Pyridinium Compounds / metabolism*
-
Pyridinium Compounds / pharmacology
-
Rats
-
Sulpiride / pharmacology
-
Temperature
-
Time Factors
Substances
-
Dopamine Antagonists
-
Isoquinolines
-
Piperazines
-
Pyridinium Compounds
-
diclofensine
-
1-(2-(diphenyloxy)ethyl)-4-(3-phenylallyl)piperazine
-
N-n-propylnorapomorphine
-
Potassium Chloride
-
Sulpiride
-
Apomorphine
-
1-Methyl-4-phenylpyridinium
-
Dopamine